K-36's epigenetic drug focuses on reversing the malignant programming of cancer cells. This approach aims to resensitize tumors to other treatments, making combination therapies the core strategy for achieving more durable responses, rather than relying on monotherapy to kill cells directly.
While scientifically exciting, pioneering a new biological pathway makes investors more conservative, as there is no proven path to follow. K-36's CEO notes this paradox: it requires more effort to educate investors and define a new space compared to a 'fast-follower' company with a clearer, pre-validated market.
The CEO attributes fundraising success during a difficult period to having a 'real asset' in clinical trials. This highlights that in challenging capital markets, investors prioritize tangible progress. A company with a drug candidate in human testing is more attractive than one with a promising but unproven discovery platform.
K-36's target, NSD2, can both initiate certain cancers (a founding driver) and help other cancers survive treatment pressure (a dependency). This dual role makes it a highly valuable target because it is relevant across different stages and types of cancer, justifying building an entire company around it.
K-36's lead drug was acquired from Novartis not because it was a failed asset, but because it became available during a strategic reorganization. This illustrates a key opportunity for biotech startups: licensing promising preclinical assets that no longer fit a large pharmaceutical company's immediate development focus.
K-36's strategy starts with multiple myeloma patients having the T414 translocation, a small, well-defined group where the drug's biological mechanism is strongest. This approach aims to secure a clear clinical proof-of-concept before expanding to broader, biomarker-defined populations, thus de-risking development.